Monograph Details
|
|
Hematology
> Thromboembolic disorders
|
|
ANGIOMAX |
| Manufacturer |
|
The Medicines Company |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Anticoagulant (thrombin inhibitor). |
| Generic Name |
|
Bivalirudin 250mg/vial; pwd for IV inj after reconstitution and dilution. |
| Indications |
|
With aspirin: anticoagulation in unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). Patients with, or at risk of, heparin–induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS) undergoing percutaceous coronary intervention (PCI), and in patients undergoing PCI with provisional use of glycoprotein IIb/IIIa (GPI). |
| Children |
|
<18yrs: Not recommended. |
| Adults |
|
Give with aspirin 300–325mg daily: initiate 0.75 mg/kg IV bolus (may give additional bolus of 0.3 mg/kg after 5 min if needed), followed by 1.75 mg/kg/hr for duration of PCI procedure. May continue infusion up to 4hrs post-procedure; after 4hrs, may give additional infusion of 0.2 mg/kg/hr up to 20 hrs, if needed. Renal impairment: CrCl <30 mL/min: reduce infusion rate to 1 mg/kg/hr; hemodialysis: 0.25 mg/kg/hr. |
| Contraindications |
|
Active major bleeding. |
| Precautions |
|
Consider stopping if symptoms of bleeding occur. Increased risk of thrombus formation with brachytherapy. Diseases associated with an increased bleeding risk. Pregnancy (Cat. B). Nursing mothers. |
| Interactions |
|
Increased bleeding risk with warfarin, heparin, thrombolytics. |
| Adverse Reactions |
|
Bleeding, back pain, pain, headache, GI upset, hypo- or hypertension, inj site pain, urinary retention. |
| How Supplied |
|
Single-use vial—1 |
|
|
|
|
